Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

TB test firm completes second tranche of series D

This article was originally published in Clinica

Executive Summary

Oxford Immunotec, a specialist in T cell measurement, has closed the second tranche of a $26m series D financing. The first tranche was completed in July 2009. The round was led by New Leaf Venture Partners, and included contributions from new investor Kaiser Permanente and existing shareholders. The financing will allow Oxford Immunotech to accelerate commercialisation of its flagship product, the T-SPOT.TB test. The lab-based cellular blood test is designed to diagnose tuberculosis and latent TB infection by measuring T cells that have been activated specifically by Mycobacterium tuberculosis antigens. It is currently marketed in the US, Europe, Canada and over 40 other countries worldwide. The funds will also be used to develop new diagnostic products from the UK company's platform T-SPOT technology.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT094619

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel